| Project/Area Number |
24790307
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Pathological medical chemistry
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
TAGUHI Keiko 東北大学, 加齢医学研究所, 助教 (20466527)
|
|---|
| Project Period (FY) |
2012-04-01 – 2014-03-31
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2012: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | Nrf2 / 肝臓 / 増殖 / 門脈枝結紮 / 転写因子 / 肝肥大 |
|---|
| Research Abstract |
Hepatectomy is a standard therapy in liver cancer patients. Massive hepatectomy is possible to lead to liver failure. Portal vein embolization increases liver size and reduces complications. Therefore, portal vein embolization is accepted before hepatectomy to prevent liver failure. Molecular mechanisms in portal vein embolization remain elusive. In this study, portal vein branch ligation is performed in mice. We found that a transcription factor Nrf2 contributes to liver proliferation. Further more, a pre-treatment of an Nrf2 activator accelerates liver hypertrophy after portal vein branch ligation. An Nrf2 activator may be effective for enhancement of hypertrophy after portal vein embolization in liver cancer patients.
|
